The purpose of the present study was to assess the effectiveness of genetically modified B-cells co-expressing CD40L in combination with CD70, OX40L, and 4-1BBL to provide costimulatory signals to CD8 T-cells, as an alternative source of autologous APCs for cancer immunotherapy. The gene discussed is CD40LG; the disease is cancer.